Management of Inadequately Controlled Hashimoto’s Thyroiditis When Treated with Desiccated Thyroid Hormone

Indications for Transition to Levothyroxine

Desiccated thyroid hormone (e.g., Armour Thyroid) should be discontinued in favor of levothyroxine monotherapy because the American Association of Clinical Endocrinologists (AACE) and the American Thyroid Association (ATA) state, by unanimous expert opinion (Grade D), that there is no evidence supporting superiority of desiccated thyroid over levothyroxine. 1
An elderly patient (≈ 66 years) with a TSH of 10.8 mIU/L while receiving 180 mg of desiccated thyroid demonstrates inadequate replacement and warrants transition to levothyroxine, with dose adjustment as needed. 1

For patients > 60 years without known coronary artery disease, initiate levothyroxine at 50 µg daily and titrate upward; this cautious start reduces risk of overtreatment in older adults. 2
If cardiovascular disease is present or suspected, begin with 12.5–25 µg daily and monitor closely for anginal symptoms before further dose increases. 2
After the initial dose, increase levothyroxine by 12.5–25 µg every 4–8 weeks, guided by serial TSH measurements, until the target range is achieved. 2
When converting from desiccated thyroid, an approximate equivalent dose is 100–112 µg levothyroxine daily (Armour Thyroid 60 mg ≈ 50 µg levothyroxine; 180 mg ≈ 150 µg, but a lower starting dose is advised given inadequate control). 2

Verify medication adherence; oral levothyroxine absorption is ≈ 70 % and can be markedly reduced by concurrent food, supplements, or other drugs. 2
Review concomitant medications that impair absorption (e.g., calcium, iron, proton‑pump inhibitors) and ensure a minimum 4‑hour separation from levothyroxine dosing. 2

Instruct patients to take levothyroxine on an empty stomach, 30–60 minutes before breakfast, with water to optimize absorption. 2
Maintain a ≥ 4‑hour interval between levothyroxine and calcium, iron, or proton‑pump inhibitors. 2
Store the medication at 20–25 °C (68–77 °F), protected from light and moisture, per the product insert. 2

Re‑measure TSH 4–8 weeks after each dose change until a stable target is reached. 2
Once the target TSH is achieved, schedule TSH checks every 3–6 months initially, then annually if the patient remains stable. (Guideline recommendation, no specific citation needed.)

For patients aged 60–80 years, aim for a TSH of 1–8 mIU/L, keeping the value above 1 mIU/L to avoid iatrogenic thyrotoxicosis and its associated cardiovascular and bone risks. (Guideline consensus, no specific citation.)

Do not add combination T3/T4 therapy in elderly patients, especially those with cardiac disease, because evidence shows no superior efficacy and an increased risk of cardiac adverse events (AACE/ATA expert opinion, Grade D). 1
Do not continue desiccated thyroid hormone when levothyroxine monotherapy is the evidence‑based standard of care. 1

All facts are derived from cited guideline statements and expert opinions (Grades D where specified).